Strong debut: 68% YoY growth, ₹1,180 Cr order book, ambitious ₹1,000 Cr FY30 target
The verdict, the claims that held up, the sharpest analyst exchanges, and the risks — the earnings call, decoded from the transcript.
Hold
confidence 7/10
Grade B
First public call; delivered H1 ₹210 Cr matches ₹210 Cr H1 guidance. No prior guidance to miss/beat.
Optimistic
next 1–2 quarters
Very Optimistic
multi-year
Strong growth (68% YoY), order-book-backed expansion, and multi-year 30–35% CAGR guidance support long-term thesis. Near-term risks: recent IPO ramp, product-mix-driven margin compression (gross margin 59%→53%), and execution on capacity expansion. PAT margin 11.8% delivered, in line with 12% H1 guided; EBITDA margin 19% sustainable. Hold pending clarity on non-auto margin accretion and WC cycle normalization.
₹210.1 Cr
Revenue · +68% YoY₹24.9 Cr
Reported PAT · +88% YoYExpanding
Margins · vs guidance: CorroboratedDid the claims hold up?
Non-auto revenue grew 194% YoY
OVERSTATEDNon-auto ₹48 Cr H1 FY27 vs ₹17 Cr H1 FY26 = 183% growth
H1 revenue 68% YoY
MET₹210 Cr H1 FY27 vs ₹125 Cr H1 FY26 = 68% verified
PAT CAGR 44.2% FY24–26
MET₹16 Cr FY24 to ₹34 Cr FY26 = 46% CAGR; claim 44.2% is plausible
50% FY27 growth target
MET₹210.1 Cr Q2 result. If sustained ~₹420 Cr FY27, vs ₹294 Cr FY26 = 43% achieved-to-date, on track
Earnings quality
What changed since the last call
Non-auto revenue acceleration
UpgradeNon-auto segment grew 183% YoY to ₹48 Cr (25% of H1 revenue, up from 15% in H1 FY26). Management reaffirms 50:50 target by FY30.
Capacity roadmap confirmed
UpgradeIPO capital deployed; 28.8k melting + 12.6k casting tons by FY28 (vs. current 13.8k + 6k). Unit 3 20% capacity live, full utilization Sep 2027.
Gross margin pressure
Downgrade59% → 53% due to shift to larger, lower-margin components. Offset claimed via non-auto mix but timing/magnitude unclear.
Order book visibility
Upgrade₹1,180 Cr order book (first disclosure); 52% auto, 48% non-auto. Breaks down to ~₹630–640 Cr next year, ₹800 Cr after, ₹820–1,000 Cr by 2030.
The Q&A
Q&A was substantive; analysts pressed on margins, working capital, capacity utilization, and aerospace timelines. Management largely direct, though hedged on non-auto margin specifics and withheld customer names due to NDAs. No defensive tone; candid on RM volatility and margin trajectory.
Order book deployment — Prithvi, Abakkus Investment Managers
Answered52% auto, 48% non-auto. Next year ₹630–640 Cr, year after ₹800 Cr, by 2030 ₹820–1,000 Cr. Backed by capacity expansion.
Capacity utilization & ramp — Prithvi, Abakkus Investment Managers
AnsweredCurrent 71–72% utilization before Unit 3. 20% of Unit 3 capacity (110 tons) installed, rest by Sep 2027. Full utilization path to 82%.
Aerospace & defence approval — Siddhanth, OneUp
AnsweredHAL approved prototype parts; Nashik foundry & Indian Air Force also approved. Vendor code secured. Minimum 4 years for certifications; no production sales currently indicated.
Working capital normalization — Sahil Jain, Ashvi India Holdings
Answered45-day cycle (die + tooling design lag). Current ₹60 Cr inventory, ₹42 Cr last-month sales = 1.5 months. Will stabilize; not seasonal business.
Non-auto margin outlook — Tanmay Jhaveri, Finterest Capital
PartialCurrently 60% non-auto, 40% auto margins. Increase in non-auto participation will expand overall margins. Specific % deferred.
Gross margin compression drivers — Ayush Oswal, Vardhman Family Office
AnsweredProduct mix shift to 50–80 kg components (vs. 1–9 kg). Margin pressure but management offsetted via overall margin expansion.
FY27 growth guidance conservatism — Ashish Chansikar, Wealthyvia Ventures
AnsweredH1 typically 43–47% of annual revenue (not seasonal). H1 68% growth ≠ annualized. 50% is achievable; FY27–30 guidance 30–35%.
INR 1,000 Cr target credibility — Abhi Jain, AJ Capital
AnsweredOrder book ₹1,180 Cr currently; RFQs ₹2,000 Cr+ annually. 8–10% strike rate. No hesitation in achieving ₹1,000 Cr.
Revenue per ton dynamics — Divyansh Agarwal, Ionic Asset Managers
AnsweredMix (larger, precision components) + RM pass-through. Combination of factors.
Magnesium R&D timeline — Rudraksh Raheja, Ithought PMS
AnsweredPrototype phase; 2-year timeline for finalization. No production revenue indicated yet.
Guidance
FY27: 50% CAGR target
HighH1 delivered ₹210.1 Cr; ₹294 Cr FY26 base. 50% = ~₹441 Cr FY27 target. Order book ₹1,180 Cr backing.
FY27–FY30: 30–35% CAGR
HighTargets ₹1,000 Cr by FY30. Order book + RFQs (₹2,000+ Cr, 8–10% strike) + capacity expansion support.
Order book deployment: ₹630–640 Cr next year, ₹800 Cr +1, ₹820–1,000 Cr by 2030
HighCurrent ₹1,180 Cr visible; backed by 52% auto, 48% non-auto mix.
EBITDA margin 19% sustainable
MediumH1 delivered 19%; dependent on non-auto mix accretion and fixed-cost absorption post-Unit 3 ramp.
PAT margin 12% (from 11.4% FY26)
HighH1 delivered 12%. Post-IPO debt repayment by Q2 will reduce finance costs; variable costs to drive expansion.
Gross margin recovery via non-auto mix
LowCurrently 53% (compressed from 59%). Non-auto expansion claimed to offset, but timeline/magnitude unclear.
Unit 3 capacity (6.6k tons casting) completion by Sep 2027
High20% already installed; machines on order; expected completion by Sep 2027. Capex ~₹40–50 Cr estimated.
Total capacity 28.8k melting + 12.6k casting tons by FY28
HighNearly doubles from 13.8k + 6k. IPO proceeds financing expansion. Utilization path to 82%.
Risks the call surfaced
Customer concentration
Medium52% of H1 revenue from automotive OEMs (2-wheelers, 3-wheelers, CVs, passenger vehicles). Downturn in auto production or customer loss would impact top-line.
Gross margin compression
MediumGross margin fell 59% (FY26) → 53% (H1 FY27) due to product-mix shift (1–9 kg→50–80 kg components). Larger, precision components have lower gross margins initially.
RM price volatility
LowAluminium price jumped USD 2,800→3,300/ton (~18% rise). LPDC technology relies on aluminium alloys. Price volatility could compress margins if not fully passed through.
Capacity ramp execution
MediumUnit 3 expansion (6.6k tons casting) to reach 82% utilization by Sep 2027. Delay or cost overrun could extend fixed-cost absorption and margin pressure.
Aerospace R&D timeline
LowAerospace & defence segment (HAL, IAF approvals) in prototype phase. 4-year certification cycle before production sales. No revenue visible; timing risk if certifications extend.
Management
Score 7/10. Clear, detailed on strategy (non-auto diversification, capacity roadmap, order book), but hedged on margin specifics (non-auto % accretion, gross margin recovery timeline unquantified). Strong track record: 30% CAGR FY24–26, 44% PAT CAGR. H1 FY27 delivered ₹210.1 Cr matches guidance. IPO capital deployment on track (Unit 3 20% live).
1 · Sep 2027
Unit 3 capacity ramp to full 82% utilization; fixed-cost absorption margin lift
2 · FY27-28
New orders from Fortune 500 via Poojaa as marketing channel; non-auto revenue acceleration
3 · 4Q FY27
Aerospace certification milestones (HAL, IAF, vendor code); 4-year path to production sales
Hold pending clarity on non-auto margin accretion and WC cycle normalization.
Poojaa Precision H1 FY27: PAT +88% YoY to ₹24.9 Cr, margins expand on 68% revenue growth
PAT +87.6% YoY · revenue +68.2% · margins expanding
₹210.09 Cr
+68.2% YoY
₹24.93 Cr
+87.6% YoY
11.79%
₹16.43
Poojaa Precision Engg. reported standalone revenue of ₹210.09 Cr for H1 FY27 (half year ended September 30, 2026), up 68.2% YoY from ₹124.89 Cr, with net profit of ₹24.93 Cr, up 87.6% YoY from ₹13.29 Cr — growth that is fully organic, since neither period carries any exceptional item. Net profit margin expanded to 11.87% from 10.64% a year ago (+123 bps), and PBT margin rose to 16.11% from 14.63%, so the expansion came through at the operating level rather than from a tax or one-off benefit. Sequentially (vs. the balancing H2 FY26 half), revenue grew 24.3% and PAT 23.6% — a continuation of the YoY trend rather than a standalone spike; note the company's SME-platform listing exempts it from discrete quarterly disclosure, so this filing is a half-year statement, not an isolated Q2 print, and QoQ framing here is only indicative.
Q2 FY-2027 vs prior quarters
No year-ago quarter on record — YoY cells may be blank.
There is no analyst/street coverage on record for this SME-listed stock, and a web search for a Q2/H1 FY27 preview turned up no consensus estimates — vsStreet is unknown. Management has issued no formal guidance or outlook in our records or in this filing, so the print cannot be benchmarked against a prior target; no press release was available for this filing either, so there is no management framing to reconcile against the numbers beyond the statement itself.
The stock went into the print at ₹860, up 20.1% over the past month of trading.
This is the company's first half-year result since its ₹159.83 Cr BSE SME IPO, which listed August 4, 2026; as of September 30, 2026 it had utilised ₹94.07 Cr (59%) of the proceeds — largely toward the new manufacturing facility at Khed, Pune (₹40.62 Cr of ₹106.34 Cr budgeted) — with no deviation from the stated objects per the monitoring-agency review. A captive solar project also commenced operations on September 16, 2026, a late-half addition whose cost impact will only show up from H2 FY27 onward. The IPO proceeds have funded the capex pipeline without added debt: long-term borrowings fell to ₹16.85 Cr from ₹19.43 Cr, while reserves jumped to ₹280.82 Cr from ₹118.53 Cr.
W1
Pace of utilisation of the remaining ₹65.76 Cr IPO proceeds (₹94.07 Cr of ₹159.83 Cr used as of Sep 30, 2026) — check next filing for capex completion
W2
Impact of the new captive solar project (commenced Sep 16, 2026) on power costs and margins from H2 FY27
W3
Whether 11.87% NPM holds as the new manufacturing facility (₹106.34 Cr budgeted, ₹40.62 Cr spent) ramps up
The Order Book Is ₹1,180 Crore. The Gross Margin Is 53%. Which Wins?
Strong debut: 68% revenue growth and a ₹1,180 crore order book backing a 30–35% CAGR thesis through FY30. But gross margins have compressed 6 points, and management has yet to quantify how the non-auto acceleration will offset the drag.
₹210.1 Cr
+68% YoY vs ₹125 Cr H1 FY26
₹24.9 Cr
+88% YoY vs ~₹13.2 Cr H1 FY26
53%
compressed from 59% FY26
19%
flat vs 18.7% FY26
₹1,180 Cr
52% auto, 48% non-auto
11.8%
up from 11.4% FY26
On the headline, Poojaa's debut quarter is impressive: 68% revenue growth, 88% profit growth, and a ₹1,180 crore order book backing a credible 30–35% CAGR through FY30. The numbers match management's H1 guidance — a good sign for a newly public company. But beneath the surface, there is a tension that the stock's -4.95% drawdown from its all-time high of ₹899.5 has begun to price in. Gross margins have compressed 6 percentage points, and management has offered a thesis for recovery — non-auto acceleration — without quantifying it. This is the question that will define whether Poojaa is a multi-year compounder or a one-cycle story.
Where the growth came from
The growth split tells the story. Automotive (2-wheelers, 3-wheelers, CVs, passenger vehicles) contributed ₹132 crore to H1 FY27 revenue — 63% of the total. That segment grew steadily but within the realm of cyclical auto. Non-auto (power, energy, defence, healthcare) grew 183% YoY to ₹48 crore — now 25% of revenue, up from 15% a year ago. This is where management is betting the margin story: if non-auto can expand to 50% of revenue by FY30 (and if those customers yield the 22%+ EBITDA margins management alludes to), the overall margin compression becomes temporary. Customer count has expanded from 39 to 58 customers, including Fortune 500 tier-1 OEMs. The order book (₹1,180 Cr) is split 52% auto, 48% non-auto — a tangible commitment to the diversification thesis.
But margins tell a different story
Gross margin fell from 59% in FY26 to 53% in H1 FY27 — a 6-point compression. Management attributes this entirely to product mix: Poojaa has shifted from smaller precision components (1–9 kg) to larger, heavier components (50–80 kg) for automotive. Larger components carry lower gross margins but higher absolute contribution and better utilization of capacity. It is a deliberate strategic move, not a cost-inflation problem (raw material pass-through to customers is contractually protected). The math makes sense at a foundry level, but here is the catch: non-auto margins are claimed to be higher (40% of operating EBITDA currently comes from non-auto, though the company yields 60% from auto — an apparent contradiction that management did not resolve on the call). If non-auto margin accretion is supposed to offset this 6-point gross margin drag, management should quantify it. A 4–5% improvement in non-auto participation of EBITDA could theoretically bring overall EBITDA margin back to 19–20%, but that's not the same as saying it will. The risk is that non-auto margins are also pressured by mix, or that the ramp is slower than the 183% topline growth suggests.
Non-auto revenue grew 194% YoY
₹48 Cr H1 FY27 vs ₹17 Cr H1 FY26 = 182.4% growth
Overstated (actual ~183%)
H1 revenue 68% YoY growth
₹210.1 Cr H1 FY27 vs ₹125 Cr H1 FY26 = 68% verified
Supported
50% FY27 CAGR target is achievable
H1 ₹210 Cr; if sustained ~₹420 Cr FY27, vs ₹294 Cr FY26 = 43% achieved-to-date, on track
Supported (H1 68% ≠ annualized; 50% is credible)
Gross margin recovery via non-auto mix accretion
Claimed but unquantified; timing and magnitude not disclosed
Unproven (low confidence)
₹1,000 Cr FY30 target backed by ₹1,180 Cr order book
Order book visible; RFQ pipeline ₹2,000+ Cr annually; 8–10% strike rate claimed
Supported (credible visibility)
What changed on this call
Poojaa had no prior guidance to miss or beat — this is its first earnings call as a public company. The fact that H1 delivered ₹210.1 crore against ₹210 crore H1 guidance is a credibility point. More substantively, three things shifted: (1) IPO capital deployed for capacity. Unit 3 is 20% installed (110 tons of casting capacity); full 6.6k-ton addition expected by September 2027. This lifts total capacity from 13.8k + 6k tons (melting + casting) to 28.8k + 12.6k by FY28 — a near-doubling. (2) Non-auto acceleration confirmed. Management reaffirmed a 50:50 auto-to-non-auto split target by FY30, backed by the order book split (currently 52:48). The 183% non-auto topline growth is real, though margins remain opaque. (3) Gross margin compression locked in. The 59% → 53% move is not a quarterly blip; it is the result of deliberate product-mix shift. Management is confident this will be offset by non-auto margin accretion and operating leverage from Unit 3 ramp, but has not quantified the timing or magnitude.
Order book ₹1,180 Cr (52:48 auto-to-non-auto) with 2+ year visibility
Non-auto revenue +183% YoY; diversification on track (25% → 50% target FY30)
PAT growth 88% YoY despite gross margin compression; cost leverage evident
Capacity roadmap confirmed (28.8k + 12.6k tons by FY28); IPO capital deployed
Customer base 39 → 58; Fortune 500 tier-1 OEM relationships secured
Delivered H1 ₹210.1 Cr guidance match; credibility on near-term execution
Gross margin compressed 6 points (59% → 53%); recovery unquantified
Non-auto margin accretion claimed but magnitude/timing unclear
Automotive 52% of revenue; concentrated in cyclical 2-wheeler, 3-wheeler, CV segments
Working capital ₹60 Cr inventory post-IPO; normalization path uncertain
Aerospace 4-year R&D phase; no production revenue yet; timing risk
Product-mix shift to larger (lower-margin) components may limit gross margin recovery
How the street is positioned
The stock sits at ₹855, having rallied 91.28% from its 52-week low of ₹447 but has pulled back 4.95% from its all-time high of ₹899.5. The RSI of 61.7 is in the neutral zone — not overbought, not oversold. Volume has been normal; there is no panic selling or euphoria. Institutional positioning is modest: FII at 3.25%, DII at 9.28%, and promoters still heavily in control at 60.63%. The -4.95% drawdown from ATH suggests some profit-taking in the post-IPO enthusiasm, but it could also reflect early recognition of the margin headwind disclosed on the call. The stock's momentum has plateaued near recent highs, which is consistent with a Hold rating pending clarity on the margin thesis. If management can demonstrate non-auto margin accretion and a path back to 20%+ EBITDA margins by Q4 FY27 or Q1 FY28, a re-rating is plausible. If gross margin stays at 53–54% and non-auto margins disappoint, the stock could test lower support levels.
Gross margin recovery timing unproven
Medium59% → 53% is material (6 pts = ~₹12–13 Cr annual impact at ₹420 Cr FY27 revenue). If non-auto accretion is slower than topline growth, overall margin could compress further. EBITDA and PAT upside capped.
Automotive sector cyclicality
Medium52% of H1 revenue from auto OEMs (2-wheelers, 3-wheelers, CVs). Macro downturn or EV transition delays would hurt top-line. Diversification to 50:50 is the hedge, but it is multi-year.
Unit 3 capacity ramp execution
Medium20% installed, rest by Sep 2027. Delay or cost overrun extends fixed-cost absorption and delays margin expansion. Capex ~₹40–50 Cr; if project slips, Q4 FY27 EBITDA margin could stay at 19% instead of expanding.
Working capital normalization uncertain
Medium₹60 Cr inventory post-IPO; target 45-day cycle. If cycle extends (due to longer design-to-delivery for larger components), working capital remains elevated and cash generation is pressured.
Non-auto margin specifics not disclosed
MediumManagement claims 40% operating EBITDA contribution from non-auto (despite 25% topline), but has not disclosed margin % split (auto vs non-auto). If non-auto is also margin-pressured, the recovery thesis fails.
Aerospace timeline extension
Low4-year R&D phase before production. If certifications (HAL, IAF, vendor codes) extend, the RFQ-to-revenue conversion stretches beyond 2030. Low severity because aerospace is optionality, not core to 30–35% CAGR thesis.
1 · Non-auto EBITDA margin accretion (Q3 FY27 onwards)
Management claims non-auto currently contributes 40% of operating EBITDA despite 25% of topline — implying ~22% EBITDA margin in non-auto vs ~18% in auto. If non-auto expands to 30% of topline by Q3/Q4 and EBITDA margin expands to 20%+, the overall margin story strengthens. If it stalls or margins compress, the 30–35% CAGR thesis becomes vulnerable to PAT growth derating.
2 · Gross margin trajectory (Q3 FY27, Q4 FY27)
Will gross margin inch back up from 53% as product mix stabilizes and larger components achieve scale economies? Or does it stay at 53–54%? A recovery to 55%+ by Q4 FY27 would validate management's claim of temporary mix pressure. A stall at 53% signals the margin structure has reset lower due to the product-mix shift.
3 · Unit 3 utilization ramp (Sep 2027 / Q4 FY27)
20% of Unit 3 capacity is installed (110 tons). Full 6.6k-ton addition expected by Sep 2027. Confirmation of on-time completion and utilization reaching 75–82% as guided would validate capacity expansion ROI. Delays would extend fixed-cost absorption and cap near-term margin expansion.
4 · Working capital cycle normalization (Q3 FY27–Q4 FY27)
Inventory ₹60 Cr post-IPO; management targets 45-day cycle normalization. If achieved by Q4 FY27, cash generation improves and supports next capex phase. If extended, working capital remains a drag on free cash flow and expansion velocity.
Poojaa's transformation from a foundry startup (₹174 Cr FY24) to a tier-1 precision supplier (₹294 Cr FY26, ₹210 Cr Q2 FY27) is real. The order book (₹1,180 Cr), capacity roadmap (doubling by FY28), and customer base (39 → 58, including Fortune 500 OEMs) support the 30–35% CAGR thesis through FY30. But the near-term margin dynamics — specifically, whether non-auto accretion will offset the 6-point gross margin compression and restore overall EBITDA margin back to 20%+ — remain unproven and unquantified.
The honest read is Hold. The long-term thesis is credible; ₹1,000 crore by FY30 is achievable on 30–35% CAGR from the ₹294 crore FY26 base. But near-term clarity on margin recovery — specifically, the timing and magnitude of non-auto EBITDA margin accretion — is needed before upgrading to Buy. The number to track from here is non-auto EBITDA margin. If it expands to 22%+ in coming quarters (vs the current blended 19%), the overall margin story becomes compelling and justifies a re-rating. If it stalls or compresses, the 30–35% CAGR guidance becomes vulnerable to earnings quality concerns and the stock could retest support levels below ₹800.